Stimulants vs Nonstimulants

CLASS COMPARISON · FROM FDA LABELS AND PUBLISHED ANALYSES

Reviewed by Tariq Halim, MD · Last medical review: October 29, 2026 · Editorial policy

This site covers 32 stimulant products (methylphenidates and amphetamines) and 6 nonstimulant products (atomoxetine, viloxazine, guanfacine and clonidine). Network meta-analyses and head-to-head trials summarized below compare the two groups; the table lists label facts.

Side-by-side facts (from the product pages)

Counts and schedules are totals of each product page’s key facts (from its FDA label). Centanafadine (Simtriyo) is grouped separately on this site (newer mechanism).

StimulantsNonstimulants
Classes on this siteMethylphenidates, AmphetaminesNonstimulants
Products on this site326
Active ingredientsamphetamine, dexmethylphenidate, dextroamphetamine, lisdexamfetamine, methamphetamine, methylphenidate, serdexmethylphenidateatomoxetine, clonidine, guanfacine, viloxazine
DEA schedule (labels)Schedule II controlled substance (CII) (32 of 32)Not a controlled substance (6 of 6)
Generic available21 of 32 products4 of 6 products

What studies compare them

Network meta-analyses and head-to-head trials (or pooled analyses of them) comparing stimulant and nonstimulant medicines, from this site’s verified evidence base. Switch on the clinician view for effect sizes.

  • Network meta-analysis

    ADHD medicines (class)

    A large analysis of 133 short-term trials found that every ADHD medicine studied worked better than placebo on clinician ratings in children and teens. Amphetamines had the largest average effect, and methylphenidate was the only medicine also shown to beat placebo on teacher ratings. Amphetamines and guanfacine led to more stopping for side effects than placebo in children. Weighing benefit and side effects, the authors favored methylphenidate first in children and amphetamines first in adults. There was too little data to judge effects beyond about 12 weeks.

    Network meta-analysis of 133 double-blind RCTs (efficacy near 12 wk: 10,068 children/adolescents; 8,131 adults). Children, clinician-rated SMD vs placebo: amphetamines −1.02 (95% CI −1.19 to −0.85), methylphenidate −0.78 (−0.93 to −0.62), atomoxetine −0.56 (−0.66 to −0.45). Teacher-rated: only methylphenidate (−0.82, −1.16 to −0.48) and modafinil separated from placebo. Adults, clinician-rated: amphetamines −0.79 (−0.99 to −0.58), methylphenidate −0.49 (−0.64 to −0.35), atomoxetine −0.45 (−0.58 to −0.32). Discontinuation for adverse events vs placebo: amphetamines OR 2.30 (1.36–3.89) in children and 3.26 (1.54–6.92) in adults; guanfacine 2.64 (1.20–5.81) in children; atomoxetine 2.33 (1.28–4.25) and methylphenidate 2.39 (1.40–4.08) in adults only. Head-to-head clinician-rated efficacy favored amphetamines over methylphenidate, atomoxetine and modafinil. Insufficient data at 26 and 52 weeks.

    Funding / affiliation: Non-industry (Stichting Eunethydis; UK NIHR Oxford Health BRC).

    Cortese S, Adamo N, Del Giovane C, et al. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 5(9):727-738. DOI · PubMed 30097390

  • Network meta-analysis

    ADHD treatments in children and teens (class)

    Across 190 trials in children and teens, methylphenidate, amphetamine, atomoxetine, guanfacine and clonidine all worked better than placebo. Methylphenidate and amphetamine appeared more effective than atomoxetine and guanfacine. Behavioral therapy combined with a stimulant appeared better than either medicine type alone. Most effective medicines also caused harms such as reduced appetite, weight loss and sleep problems.

    Bayesian network meta-analyses of 190 RCTs (52 interventions, 26,114 participants; ≥3 weeks follow-up). Medications more efficacious than placebo: methylphenidate, amphetamine, atomoxetine, guanfacine, clonidine. Methylphenidate and amphetamine more efficacious than atomoxetine and guanfacine; methylphenidate and clonidine better accepted (all-cause discontinuation) than placebo and atomoxetine. Behavioural therapy plus stimulants appeared superior to stimulants or nonstimulants alone. Harms included anorexia, weight loss and insomnia. Results expressed as ORs with credible intervals (not reproduced here).

    Catalá-López F, Hutton B, Núñez-Beltrán A, et al. (2017). The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. PLoS One 12(7):e0180355. DOI · PubMed 28700715

  • Network meta-analysis

    Adult ADHD treatments (class)

    In adults (113 trials), stimulants and atomoxetine were the only treatments that reduced core symptoms on both self-ratings and clinician ratings at 12 weeks. Several psychological approaches (such as CBT and mindfulness) helped only on clinician ratings. Atomoxetine and guanfacine were stopped more often than placebo.

    Component NMA, 113 RCTs (14,887 adults). 12-week core symptoms: atomoxetine SMD −0.38 self-rated (−0.56 to −0.21), −0.51 clinician-rated (−0.64 to −0.37); stimulants about −0.39 self-rated (CI −0.52 to −0.26) and −0.61 clinician-rated (−0.71 to −0.51). CBT (−0.76), cognitive remediation, mindfulness, psychoeducation and tDCS beat placebo on clinician-rated measures only. Acceptability worse than placebo: atomoxetine OR 1.43 (1.14–1.80), guanfacine 3.70 (1.22–11.19).

    Ostinelli EG, Schulze M, Zangani C, et al. (2025). Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. Lancet Psychiatry 12(1):32-43. DOI · PubMed 39701638

  • Network meta-analysis

    ADHD medicines in children (class)

    An industry-funded network analysis of 36 trials ranked placebo-adjusted symptom improvement as largest for lisdexamfetamine, then extended-release methylphenidate, then guanfacine ER, then atomoxetine. These are indirect comparisons.

    Industry-funded indirect (network) comparison.

    Bayesian NMA of 36 RCTs (6–17 y). ADHD-RS-IV change vs placebo: lisdexamfetamine −14.98 (95% CrI −17.14 to −12.80), MPH ER −9.33 (−11.63 to −7.04), guanfacine ER −8.68 (−10.63 to −6.72), atomoxetine −6.88 (−8.22 to −5.49).

    Funding / affiliation: Authors affiliated with Shire (guanfacine ER and lisdexamfetamine manufacturer) per PubMed record.

    Joseph A, Ayyagari R, Xie M, et al. (2017). Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. Eur Child Adolesc Psychiatry 26(8):875-897. DOI · PubMed 28258319

  • Meta-analysis

    Methylphenidate vs atomoxetine (children)

    Combining nine head-to-head trials (2,762 participants), methylphenidate and atomoxetine did not differ overall in effect or response rates. In a subgroup, long-acting OROS methylphenidate (the Concerta-type formulation) worked better than atomoxetine, while immediate-release methylphenidate did not.

    Meta-analysis of 9 RCTs (n=2,762) comparing methylphenidate and atomoxetine. Overall SMD 0.09 (95% CI −0.08 to 0.26), NS; response RR 0.93 (0.76–1.14). Subgroup: OROS methylphenidate SMD 0.32 (0.12–0.53) favoring OROS; immediate-release methylphenidate −0.04 (−0.19 to 0.12). An update (Rezaei 2016, PMID 27390695; 11 studies, 2,772) reported the same pattern (OROS SMD 0.31, 0.16–0.47).

    Hanwella R, Senanayake M, de Silva V (2011). Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry 11:176. DOI · PubMed 22074258

  • Meta-analysis

    Atomoxetine vs methylphenidate (children)

    Pooling seven direct-comparison studies (1,368 children and teens), about half responded after 6 weeks on either medicine (53.6% atomoxetine, 54.4% methylphenidate); atomoxetine met the test for being no worse.

    Pooled analysis of 7 head-to-head studies (N=1,368). Response at 6 weeks: atomoxetine 53.6% (95% CI 48.6–58.4; n=811) vs methylphenidate 54.4% (47.6–61.1; n=557); absolute difference −0.9% (−9.2 to 7.5), non-inferior.

    Hazell PL, Kohn MR, Dickson R, et al. (2011). Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis. J Atten Disord 15(8):674-83. DOI · PubMed 20837981

  • Randomized controlled trial

    Lisdexamfetamine vs atomoxetine

    In a 9-week head-to-head trial of 267 children and teens who had not done well on methylphenidate, lisdexamfetamine worked faster and reduced symptoms more than atomoxetine. Response by week 9 was 82% vs 64%.

    Head-to-head RCT, n=267 (LDX 133, ATX 134). Median time to response 12.0 vs 21.0 days (p=0.001); week-9 response 81.7% vs 63.6%; ADHD-RS-IV difference −6.5 (−9.3 to −3.6; ES 0.56). TEAEs 71.9% vs 70.9%. Companion analysis (PMID 25038977): ≥30% reduction 88.1% vs 73.7%.

    Dittmann RW, Cardo E, Nagy P, et al. (2013). Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs 27(12):1081-92. DOI · PubMed 23959815

  • Network meta-analysis

    Atomoxetine vs OROS methylphenidate (adults)

    In adults, a network analysis of trials up to 12 weeks found no significant difference in benefit between atomoxetine and OROS methylphenidate, and no difference in how often people stopped treatment.

    NMA in adults: SMD vs placebo atomoxetine 0.46 (95% CrI 0.36–0.56), OROS methylphenidate 0.51 (0.40–0.63); atomoxetine vs OROS −0.05 (−0.18 to 0.08). Discontinuation OR 0.85 (0.53–1.35).

    Funding / affiliation: Authors affiliated with Eli Lilly (atomoxetine manufacturer) per PubMed record.

    Bushe C, Day K, Reed V, et al. (2016). A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients. J Psychopharmacol 30(5):444-58. DOI · PubMed 27005307

Switching between a stimulant and a nonstimulant

No nonstimulant label on this site gives a dose conversion from a stimulant, and no stimulant label gives one from a nonstimulant: each is started at its own label starting dose and adjusted. See the switching guide for what each label does say.

Talk to your prescriber. Whether a stimulant or a nonstimulant fits best depends on the person, other conditions and side effects. Do not stop or swap a medicine without your prescriber.

Frequently asked questions

Are stimulants more effective than nonstimulants for ADHD?

Cortese 2018: A large analysis of 133 short-term trials found that every ADHD medicine studied worked better than placebo on clinician ratings in children and teens. Amphetamines had the largest average effect, and methylphenidate was the only medicine also shown to beat placebo on teacher ratings. Amphetamines and guanfacine led to more stopping for side effects than placebo in children. Weighing benefit and side effects, the authors favored methylphenidate first in children and amphetamines first in adults. There was too little data to judge effects beyond about 12 weeks. Catalá-López 2017: Across 190 trials in children and teens, methylphenidate, amphetamine, atomoxetine, guanfacine and clonidine all worked better than placebo. Methylphenidate and amphetamine appeared more effective than atomoxetine and guanfacine. Behavioral therapy combined with a stimulant appeared better than either medicine type alone. Most effective medicines also caused harms such as reduced appetite, weight loss and sleep problems. Hanwella 2011: Combining nine head-to-head trials (2,762 participants), methylphenidate and atomoxetine did not differ overall in effect or response rates. In a subgroup, long-acting OROS methylphenidate (the Concerta-type formulation) worked better than atomoxetine, while immediate-release methylphenidate did not. Individual responses vary.

Are nonstimulants controlled substances?

Stimulants on this site: Schedule II controlled substance (CII) (32 of 32). Nonstimulants on this site: Not a controlled substance (6 of 6). Schedules are from each product’s label and key facts.

Can you switch from a stimulant to a nonstimulant?

The labels give no dose conversion between stimulants and nonstimulants. The new medicine is started at its label starting dose and adjusted by the prescriber.

Are generics available?

Stimulants: 21 of 32 products on this site have a generic or authorized generic. Nonstimulants: 4 of 6. See each class page for the product list.

Sources

  • Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-738. PubMed
  • Catalá-López F, Hutton B, Núñez-Beltrán A, et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. PLoS One. 2017;12(7):e0180355. PubMed
  • Ostinelli EG, Schulze M, Zangani C, et al. Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis. Lancet Psychiatry. 2025;12(1):32-43. PubMed
  • Joseph A, Ayyagari R, Xie M, et al. Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. Eur Child Adolesc Psychiatry. 2017;26(8):875-897. PubMed
  • Hanwella R, Senanayake M, de Silva V Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry. 2011;11:176. PubMed
  • Hazell PL, Kohn MR, Dickson R, et al. Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis. J Atten Disord. 2011;15(8):674-83. PubMed
  • Dittmann RW, Cardo E, Nagy P, et al. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs. 2013;27(12):1081-92. PubMed
  • Bushe C, Day K, Reed V, et al. A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients. J Psychopharmacol. 2016;30(5):444-58. PubMed
  • Product facts: each product page’s key facts and FDA prescribing information (linked from the methylphenidates, amphetamines and nonstimulants class pages).
EDUCATIONAL INFORMATION ONLY. Not medical advice. Medication decisions require individualized assessment by a qualified clinician. Do not start, stop, switch or change the dose of a medication without your prescriber. See the medical disclaimer.